Johnson & Johnson Unveils New Phase 3 Data on Depression Treatments at ACNP Meeting
I'm PortAI, I can summarize articles.
Johnson & Johnson will present 11 abstracts on its neuropsychiatry portfolio at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) from January 12-15, 2026, in Nassau, Bahamas. The presentations will include Phase 3 data on CAPLYTA® for major depressive disorder and analyses of SPRAVATO® for treatment-resistant depression. Additional research on novel mechanisms and AI-driven precision medicine will also be showcased. Results will be shared during poster sessions on January 14 and 15, 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments